| Literature DB >> 35965492 |
Rajab Rashidi1, Yusef Omidi Khaniabadi2, Pierre Sicard3, Alessandra De Marco4, Khatereh Anbari5.
Abstract
The main objectives of this study were to (i) assess variation within fine particles (PM2.5) and tropospheric ozone (O3) time series in Khorramabad (Iran) between 2019 (before) and 2020 (during COVID-19 pandemic); (ii) assess relationship between PM2.5 and O3, the PM2.5/O3 ratio, and energy consumption; and (iii) estimate the health effects of exposure to ambient PM2.5 and O3. From hourly PM2.5 and O3 concentrations, we applied both linear-log and integrated exposure-response functions, city-specific relative risk, and baseline incidence values to estimate the health effects over time. A significant correlation was found between PM2.5 and O3 (r =-0.46 in 2019, r =-0.55 in 2020, p < 0.05). The number of premature deaths for all non-accidental causes (27.5 and 24.6), ischemic heart disease (7.3 and 6.3), chronic obstructive pulmonary disease (17 and 19.2), and lung cancer (9.2 and 6.25) attributed to ambient PM2.5 exposure and for respiratory diseases (4.7 and 5.4) for exposure to O3 above 10 µg m-3 for people older than 30-year-old were obtained in 2019 and 2020. The number of years of life lost declined by 11.6% in 2020 and exposure to PM2.5 reduced the life expectancy by 0.58 and 0.45 years, respectively in 2019 and 2020. Compared to 2019, the restrictive measures associated to COVID-19 pandemic led to reduction in PM2.5 (-25.5%) and an increase of O3 concentration (+ 8.0%) in Khorramabad.Entities:
Keywords: Air pollution; COVID-19; Health effect; O3; PM2.5
Year: 2022 PMID: 35965492 PMCID: PMC9358119 DOI: 10.1007/s00477-022-02286-z
Source DB: PubMed Journal: Stoch Environ Res Risk Assess ISSN: 1436-3240 Impact factor: 3.821
Fig.1The study area of Khorramabad, Iran
Baseline incidence (BI) and relative risk (RR) values for health outcomes, and people at risk at 95% confidence intervals (95% CI) for long-term exposure to PM2.5 and O3 concentrations (lag0-1 days) more than 10 µg m−3
| Health outcomes | BI | RR per 10 µg m−3 (95% CI) | Ref | |
|---|---|---|---|---|
| PM2.5 | ||||
| Mortality, all-cause (age ≥ 30) | 845–1832 | 1.062 (1.04–1.083) | Héroux et al. ( | |
| Mortality, IHD (age ≥ 25) | 101–177 | IER function | Burnett et al. ( | |
| Mortality, COPD (age ≥ 30) | 13–20 | IER function | Burnett et al. ( | |
| Mortality, LC (age ≥ 30) | 11–22 | IER function | Burnett et al. ( | |
| O3 | ||||
| Mortality, respiratory diseases (age ≥ 30) | 44–53 | 1.014 (1.005–1.024) | Héroux et al. ( | |
Fig. 2Time series trends of PM2.5 and O3 levels in 2019 and 2020 in Khorramabad, Iran
Fig.3(left) Correlation between PM2.5 with O3 levels, and (right) relationship between PM2.5/O3 ratio with PM2.5 during 2019 and 2020 across Khorramabad, Iran
Fig.4(left) Comparative bar between PM2.5 and O3 averages in 2018, 2019 (before COVID-19) with 2020 (during COVID-19), and (right) Cost reduction in fuel consumption in 2018, 2019 (before COVID-19) with 2020 (during COVID-19) across Khorramabad, Iran
At-risk population, estimated AP %, and the number of cases due to long-term exposure to PM2.5 and O3 using the 95% CI RR in 2019 and 2020
| Health impact | At-risk population | Estimated AP (%) | PM2.5 | O3 | ||||
|---|---|---|---|---|---|---|---|---|
| 2019 | 2020 | 2019 | 2020 | 2019 | 2020 | 2019 | 2020 | |
| Mortality, all-cause (age ≥ 30) | 134,500 | 144,200 | 3.7 (1.3–5.8) | 2.8 (2.0–5.1) | 27.5 (4.6–37) | 24.6 (21–41.2) | – | – |
| Mortality, IHD (age ≥ 25) | 79,800 | 81,580 | 5.6 (0.5– 11.9) | 6.1 (0.8– 13.85) | 7.3 (6.6–14.9) | 6.3(1.2–11.5) | – | – |
| Mortality, COPD (age ≥ 30) | 68,440 | 71,050 | 2.7 (0.5– 4.9) | 1.8 (0.2– 2.8) | 17.0 (8.9–23.6) | 19.2 (5.8–32.6) | – | – |
| Mortality, LC (age ≥ 30) | 54,600 | 60,750 | 12.8 (5.9– 21.9) | 10.4 (3.5–12.85) | 9.2 (8.31–11.2) | 6.25 (2.45–9.3) | – | – |
| Mortality, RD (age ≥ 30) | 101,560 | 112,700 | 13.6 (11.5– 15.8) | 11.6 (4.7– 16.5) | – | – | 4.7 (1.56–8.66) | 5.4 (1.8–13.42) |
Years of life lost and expected life remaining due to exposure to PM2.5 above 10 µg m−3 in 2019 and 2020
| Year | YLL (age ≥ 30) | YLL for 105/capita | ELR reduction at age 30 |
|---|---|---|---|
| 2019 | 1456 (920–2455) | 24.4 (12.87–28.0) | 0.58 (0.32–1.08) |
| 2020 | 1287 (780–1621) | 23.0 (17.8–27.5) | 0.45 (0.21–0.66) |